Similar articles

• Direct oral anticoagulants and obesity: one size fits all?

  den Exter PL, Huisman MV. den Exter PL, et al. Lancet Haematol. 2019 Jul;6(7):e341-e342. doi: 10.1016/S2352-3026(19)30092-4. Epub 2019 May 24. Lancet Haematol. 2019. PMID: 31133410 No abstract available.
• Direct oral factor Xa inhibitors in patients with morbid obesity.

  Summers KL, Mihm AE, Kenes MT. Summers KL, et al. Lancet Haematol. 2019 Sep;6(9):e446. doi: 10.1016/S2352-3026(19)30152-8. Lancet Haematol. 2019. PMID: 31471006 No abstract available.
• Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.

  Glikson E, Chavkin U, Madgar O, Sagiv D, Nakache G, Yakirevitch A, Wolf M, Alon EE. Glikson E, et al. Laryngoscope. 2019 Jan;129(1):119-123. doi: 10.1002/lary.27400. Epub 2018 Oct 16. Laryngoscope. 2019. PMID: 30325496
• Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.

  Marcy TR, Truong T, Rai A. Marcy TR, et al. Consult Pharm. 2015 Nov;30(11):644-56. doi: 10.4140/TCP.n.2015.644. Consult Pharm. 2015. PMID: 26629800 Review.
• Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.

  Piccini JP, Lopes RD, Mahaffey KW. Piccini JP, et al. Curr Opin Cardiol. 2010 Jul;25(4):312-20. doi: 10.1097/HCO.0b013e32833a524f. Curr Opin Cardiol. 2010. PMID: 20520539 Review.